Evidence Hub

Next-Generation Artificial Intelligence in Clinical Trial Design, Conduct, and Analysis: A Paradigm Shift in Clinical Research

Ashish Pandey, Ankit Galav, Komal Mittal, Yuvraj Dhanesha, Khushi Maheshwari, J. Jacob

International Journal of Clinical Case Reports and Reviews, 2026

Abstract

Clinical research and clinical trials serve as the fundamental framework for verifying the safety and therapeutic efficacy of novel biomedical interventions before commercial distribution (1). However, contemporary drug development paradigms encounter escalating complexities, characterized by protracted timelines, rising financial burdens and substantial operational failure rates during Phase II and Phase III evaluations (2). While classical methodologies rely heavily on population-based cohorts and manual protocols, the rapid integration of advanced Artificial Intelligence (AI) encompassing deep learning, multi-modal transformer architectures and generative large language models (LLMs) is driving a structural paradigm shift (3,4).

This comprehensive article provides an in-depth examination of how next-generation AI methodologies optimize every stage of clinical trial infrastructure. In trial design, AI pipelines streamline information gathering, refine inclusion and exclusion criteria, and simulate control cohorts using virtual digital twins. During execution, natural language processing (NLP) and multi-modal data fusion accelerate patient screening, enhance recruitment tracking and mitigate attrition via remote, sensor-based monitoring. In the analytical phase, deep convolutional neural networks (CNNs) and federated learning models elevate precision medicine through automated radiomics, digital pathology and predictive toxicity mapping. Finally, this review addresses…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free